CLDX Celldex Therapeutics22.91-0.66 (-2.8%)
CLDX Celldex Therapeutics24.51-0.09 (-0.4%)
Premarket Decliner
CLDX Celldex Therapeutics24.02-0.46-1.9%
Premarket:21.08-2.94 (-12.2%)
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)
Globe NewswireTue, 19-Aug 4:01 PM
After Hours Decliner
CLDX Celldex Therapeutics24.02-0.46-1.9%
After Hours:19.30-4.72 (-19.7%)
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)
Globe NewswireTue, 19-Aug 4:01 PM
CLDX Celldex Therapeutics21.48+0.50 (+2.4%)
CLDX Celldex Therapeutics20.90-1.10 (-5.0%)